Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon
Thumbnail

No gender differences in long-term MI outcomes

A long-term study of more than 14,000 patients admitted to the hospital for MI over 24 years found adjusted mortality was equal for men and women. The results of this large, single-center study were published in the Oct. 30 issue of Circulation.

TCT.12: Miami sun shines light on clinical gray zones

The 24th annual Transcatheter Cardiovascular Therapeutics (TCT) conference took place in Miami for the first time this year, and the venue brought in a record-breaking approximate 12,000 attendees, according to TCT Chair Gregg W. Stone, MD.

EU approves Boston Sci's stent with different polymer

Boston Scientific has received CE Mark approval for its Synergy everolimus-eluting platinum chromium coronary stent system featuring an abluminal (outer) bioabsorbable polymer coating.

TCT: Mesh-covered stent shows promise for complete ST-segment resolution

MIAMI—Among patients with acute STEMI undergoing primary PCI, the MGuard micronet mesh-covered stent compared with conventional metallic stents resulted in superior rates of epicardial coronary flow and complete ST-segment resolution (STR), according to the MASTER trial presented Oct. 24 at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) conference.

Radial access benefits STEMI but not other ACS patients

Using radial access site intervention reduces the risk of adverse outcomes in STEMI patients, but it offers no increased benefit to patients with non-ST segment elevation acute coronary syndrome, according a RIVAL analysis published online Oct. 24 in the Journal of the American College of Cardiology.

TCT: Clopidogrel hypo-responsiveness predictive of complications but not death

MIAMI—Drug-eluting stent (DES) recipients who are hypo-responsive to clopidogrel are at higher risk of stent thrombosis and MI, but patients with higher levels of platelet inhibition are more likely to experience major bleeding, according to the results of the Assessment of Dual Anti-Platelet Therapy with Drug Eluting Stent (ADAPT-DES) study.

TCT: Drug-eluting balloons best therapy for DES restenosis

MIAMI—Paclitaxel-eluting balloons should be the treatment of choice for drug-eluting stent (DES) restenosis because the balloon avoids the problem of additional stent layers, according to a study presented Oct. 26 at the Transcatheter Cardiovascular Therapeutics (TCT) conference.

TCT: Abciximab can be safely delivered to STEMI patients through IV or directly to heart

MIAMI—There was no difference in myocardial damage or reperfusion injury with abciximab (ReoPro, Eli Lilly) delivered directly to the heart, called an intracoronary delivery, as compared with receiving the agent intravenously (IV) in STEMI patients, based on cardiac MR data from the AIDA STEMI MRI substudy.

Displaying 1953 - 1960 of 2712

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.